Nurix Therapeutics (NRIX) has been able to post initial positive results from both of its early-stage studies using its protein degraders known as NX-2127 and NX-5948 for the treatment of patients ...
Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the treatment of B-cell malignancies Poster presentation highlights ...
In the battle against B-cell cancers, drugs that target the enzyme Bruton tyrosine kinase (BTK) have transformed treatment. Before the first BTK inhibitor, ibrutinib, came on the market in 2013, ...
Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback